ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 56 mins

Alexion Pharmaceuticals, Inc. (ALXN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
118.83-0.43 (-0.36%)
At close: 4:00PM EDT
People also watch
REGNBMRNVRTXBIIBCELG
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close119.26
Open117.67
Bid100.76 x 100
Ask140.65 x 100
Day's Range115.58 - 119.04
52 Week Range109.12 - 162.00
Volume2,273,223
Avg. Volume2,129,406
Market Cap26.69B
Beta1.28
PE Ratio (TTM)67.52
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal7 hours ago

    [$$] Alexion Names New CEO Following Internal Sales-Practice Probe

    Alexion Pharmaceuticals Inc. named new a chief executive Monday, months after the company’s top leadership abruptly stepped down amid an internal investigation into sales practices.

  • Reuters14 hours ago

    Alexion Pharma names former Baxalta chief Ludwig Hantson CEO

    Alexion Pharmaceuticals Inc on Monday named former Baxalta CEO Ludwig Hantson to its top job, as the rare-disease drug maker seeks to regain investor confidence following the exit of top management. Hantson's appointment comes after a challenging few months for the U.S. biotech. Alexion's flagship drug Soliris, which treats two rare blood disorders, has fueled much of the company's growth, but looming competition and the drug's slowing sales growth in recent quarters have made investors jittery.

  • TheStreet.com16 hours ago

    Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

    Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.